Compounds > fusidic acid
Page last updated: 2024-09-04

fusidic acid and zithromax

fusidic acid has been researched along with zithromax in 8 studies

Compound Research Comparison

Studies
(fusidic acid)		Trials
(fusidic acid)		Recent Studies (post-2010)
(fusidic acid)		Studies
(zithromax)		Trials
(zithromax)		Recent Studies (post-2010) (zithromax)
1,7421173446,9641,2633,790

Protein Interaction Comparison

ProteinTaxonomyfusidic acid (IC50)zithromax (IC50)
30S ribosomal protein S6Escherichia coli K-120.3
30S ribosomal protein S7Escherichia coli K-120.3
50S ribosomal protein L15Escherichia coli K-120.3
50S ribosomal protein L10Escherichia coli K-120.3
50S ribosomal protein L11Escherichia coli K-120.3
50S ribosomal protein L7/L12Escherichia coli K-120.3
50S ribosomal protein L19Escherichia coli K-120.3
50S ribosomal protein L1Escherichia coli K-120.3
50S ribosomal protein L20Escherichia coli K-120.3
50S ribosomal protein L27Escherichia coli K-120.3
50S ribosomal protein L28Escherichia coli K-120.3
50S ribosomal protein L29Escherichia coli K-120.3
50S ribosomal protein L31Escherichia coli K-120.3
50S ribosomal protein L31 type BEscherichia coli K-120.3
50S ribosomal protein L32Escherichia coli K-120.3
50S ribosomal protein L33Escherichia coli K-120.3
50S ribosomal protein L34Escherichia coli K-120.3
50S ribosomal protein L35Escherichia coli K-120.3
50S ribosomal protein L36Escherichia coli K-120.3
30S ribosomal protein S10Escherichia coli K-120.3
30S ribosomal protein S11Escherichia coli K-120.3
30S ribosomal protein S12Escherichia coli K-120.3
30S ribosomal protein S13Escherichia coli K-120.3
30S ribosomal protein S16Escherichia coli K-120.3
30S ribosomal protein S18Escherichia coli K-120.3
30S ribosomal protein S19Escherichia coli K-120.3
30S ribosomal protein S20Escherichia coli K-120.3
30S ribosomal protein S2Escherichia coli K-120.3
30S ribosomal protein S3Escherichia coli K-120.3
30S ribosomal protein S4Escherichia coli K-120.3
30S ribosomal protein S5Escherichia coli K-120.3
30S ribosomal protein S8Escherichia coli K-120.3
30S ribosomal protein S9Escherichia coli K-120.3
50S ribosomal protein L13Escherichia coli K-120.3
50S ribosomal protein L14Escherichia coli K-120.3
50S ribosomal protein L16Escherichia coli K-120.3
50S ribosomal protein L23Escherichia coli K-120.3
30S ribosomal protein S15Escherichia coli K-120.3
50S ribosomal protein L17Escherichia coli K-120.3
50S ribosomal protein L21Escherichia coli K-120.3
50S ribosomal protein L30Escherichia coli K-120.3
50S ribosomal protein L6Escherichia coli K-120.3
30S ribosomal protein S14Escherichia coli K-120.3
30S ribosomal protein S17Escherichia coli K-120.3
30S ribosomal protein S1Escherichia coli K-120.3
50S ribosomal protein L18Escherichia coli K-120.3
50S ribosomal protein L2Escherichia coli K-120.3
50S ribosomal protein L3Escherichia coli K-120.3
50S ribosomal protein L24Escherichia coli K-120.3
50S ribosomal protein L4Escherichia coli K-120.3
50S ribosomal protein L22Escherichia coli K-120.3
50S ribosomal protein L5Escherichia coli K-120.3
30S ribosomal protein S21Escherichia coli K-120.3
50S ribosomal protein L25Escherichia coli K-120.3
50S ribosomal protein L36 2Escherichia coli K-120.3

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Apajalahti, J; Fox, J; Frimodt-Møller, N; Hansen, F; Loidl, G; Nagai, J; Siikanen, O; Takano, M; Vaara, M; Vaara, T1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Apajalahti, J; Fox, J; Frimodt-Møller, N; He, H; Li, J; Nation, RL; Poudyal, A; Siikanen, O; Vaara, M; Vaara, T1
Bohnert, JA; Karamian, B; Nikaido, H1
Biedenbach, DJ; Hammerschlag, MR; Jones, RN; Kohlhoff, SA; Roblin, PM1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Mazereeuw-Hautier, J1
Brennan-Krohn, T; Kirby, JE; Pironti, A1

Reviews

1 review(s) available for fusidic acid and zithromax

ArticleYear
[Impetigo].
    Annales de dermatologie et de venereologie, 2006, Volume: 133, Issue:2

    Topics: Administration, Oral; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Azithromycin; Cephalosporins; Child; Clavulanic Acid; Clinical Trials as Topic; Diagnosis, Differential; Drug Therapy, Combination; Female; Fusidic Acid; Humans; Impetigo; Infant; Male; Methicillin; Mupirocin; Ointments; Penicillins; Pregnancy; Pristinamycin; Sulfadiazine; Time Factors

2006

Other Studies

7 other study(ies) available for fusidic acid and zithromax

ArticleYear
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:9

    Topics: Animals; Anti-Bacterial Agents; Cricetinae; Fibroblasts; Gram-Negative Bacteria; Kidney Cortex; Lung; Microbial Sensitivity Tests; Microvilli; Polymyxin B; Rats; Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:8

    Topics: Animals; Anti-Bacterial Agents; Cell Membrane Permeability; Cricetinae; Cricetulus; Drug Synergism; Fibroblasts; Gram-Negative Bacteria; Guinea Pigs; Lung; Male; Microbial Sensitivity Tests; Polymyxin B; Rats; Structure-Activity Relationship

2010
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:9

    Topics: Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chlortetracycline; Dipeptides; Doxorubicin; Doxycycline; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Minocycline; Onium Compounds; Organophosphorus Compounds; Tetracycline

2010
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10

    Topics: Anti-Bacterial Agents; Chlamydia trachomatis; Fusidic Acid; Neisseria gonorrhoeae

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Synergistic Activity of Colistin-Containing Combinations against Colistin-Resistant Enterobacteriaceae.
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:10

    Topics: Anti-Bacterial Agents; Azithromycin; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Enterobacteriaceae; Fusidic Acid; Linezolid; Microbial Sensitivity Tests; Rifampin

2018